Toggle navigation
Home
Feed
Channels
Profile
Home
Feed
Channels
Profile
Medspoke's Talks
Medspoke
Medspoke
Leukemia
Published October 6, 2026
KT-253, a highly potent and selective MDM2 protein degrader, eliminates malignant myelofibrosis s...
October 7, 2026
Medspoke
Medspoke
Journal of the European Academy of Dermatology and Venereology (JEADV)
Published October 6, 2026
00:00
--:--
Targeted therapies in pemphigus vulgaris: Emerging horizons beyond rituximab.
October 7, 2026
Share
Targeted therapies in pemphigus vulgaris: Emerging horizons beyond rituximab.
https://www.medspoke.co/channel_journal?id=875&tap_id=15194
Copy Link
Email
X
Bluesky
WhatsApp
LinkedIn
Facebook
Reddit
Medspoke
Medspoke
Rheumatology (Oxford)
Published October 6, 2026
Impacts of socioeconomic status on ambulatory care sensitive condition hospitalizations in rheuma...
October 7, 2026
Why are you reporting this TALK?
